Effects of therapy using a helicase-primase inhibitor (HPI) in mice infected with deliberate mixtures of wild-type HSV-1 and an HPI-resistant UL5 mutant

Antiviral Research

Volumn 87, Issue 1, 2010, Pages 67-73

  Sukla, Soumi ^a   Biswas, Subhajit ^a,c   Birkmann, Alexander ^b   Lischka, Peter ^b   Ruebsamen Schaeff, Helga ^b   Zimmermann, Holger ^b   Field, Hugh J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b AiCuris GmbH   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antiviral resistance; Antivirals; BAY 57 1293; Helicase primase inhibitor; HSV; Murine infection model

Indexed keywords

ANTIVIRUS AGENT; BAY 57 1293; HELICASE; HELICASE PRIMASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; MOUSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS STRAIN; WILD TYPE;

AMINO ACID SUBSTITUTION; ANIMALS; ANTIVIRAL AGENTS; DNA HELICASES; DNA PRIMASE; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICE; MICE, INBRED BALB C; MUTATION, MISSENSE; TREATMENT OUTCOME; VIRAL PROTEINS;

HUMAN HERPESVIRUS 1; MURINAE; MUS; SIMPLEXVIRUS;

EID: 77953536608     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.04.008     Document Type: Article

References (27)

1. Bacon T.H., Levin M.J., Leary J.J., Sarisky R.T., Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin. Microbiol. Rev. 2003, 6:14-28.
2. Baumeister J., Fischer R., Eckenberg P., Henninger K., Ruebsamen-Waigmann H., Kleymann G. Superior efficacy of helicase-primase inhibitor BAY 57-1293 for herpes infection and latency in the guinea pig model of human genital herpes disease. Antiviral Chem. Chemother. 2007, 18:35-48.
3. Betz U.A.K., Fischer R., Kleymann G., Hendrix M., Rübsamen-Waigmann H. Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY57-1293. Antimicrob. Agents Chemother. 2002, 46:1766-1772.
4. Biswas S., Núñez Miguel R., Sukla S., Field H.J. A mutation in helicase motif IV of herpes simplex virus type 1 UL5 that results in reduced growth in vitro and lower virulence in a murine infection model is related to the predicted helicase structure. J. Gen. Virol. 2009, 90:1937-1942.
5. Biswas S., Field H.J. Herpes simplex virus helicase-primase inhibitors: recent findings from the study of drug-resistance mutations. Antiviral Chem. Chemother. 2008, 19:1-6.
6. Biswas S., Kleymann G., Swift M., Tiley L.S., Lyall J., Aguirre-Hernández J., Field H.J. A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase-primase inhibitors in their mode of interaction with the antiviral target. J. Antimicrob. Chemother. 2008, 61:1044-1047.
7. Biswas S., Tiley L.S., Zimmermann H., Birkmann A., Field H.J. Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity. Antiviral Res. 2008, 80:81-85.
8. Biswas S., Jennens L., Field H.J. The helicase primase inhibitor, BAY57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. Antiviral Res. 2007, 75:30-35.
9. Biswas S., Swift M., Field H.J. High frequency of spontaneous helicase primase inhibitor (BAY57-1293) drug resistant variants in certain laboratory isolates of HSV-1. Antiviral Chem. Chemother. 2007, 18:13-23.
10. Biswas S., Smith C., Field H.J. Detection of HSV-1 variants highly resistant to the helicase-primase inhibitor BAY 57-1293 at high frequency in two of ten recent clinical isolates of HSV-1. J. Antimicrob. Chemother. 2007, 60:274-279.
11. Biswas S., Jennens L., Field H.J. Single amino acid substitutions in the HSV-1 helicase protein that confer resistance to the helicase-primase inhibitor BAY 57-1293 are associated with increased or decreased virus growth characteristics in tissue culture. Arch. Virol. 2007, 152:1489-1500.
12. Cavanaugh N.A., Ramirez-Aguilar K.A., Urban M., Kuchta R.D. Herpes simplex virus-1 helicase-primase: roles of each subunit in DNA binding and phosphodiester bond formation. Biochemistry 2009, 48:10199-10207.
13. Crute J.J., Grygon C.A., Hargrave K.D., Simoneau B., Faucher A.-M., Bolger G., Kibler P., Liuzzi M., Cordingley M.G. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat. Med. 2002, 8:386-391.
14. Crute J.J., Tsurumi L., Zhu L.A., Weller S.K., Olivo P.D., Challberg M.D., Mocarski E.S., Lehman I.R. Herpes simplex virus 1 helicase-primase: a complex of three herpes encoded gene products. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:2186-2189.
15. Frobert E., Cortay J.C., Ooka T., Najioullah F., Thouvenot D., Lina B., Morfin F. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res. 2008, 79:28-36.
16. Kaufman H.E., Varnell E.D., Gebhardt B.M., Thompson H.W., Atwal E., Rübsamen-Waigmann H., Kleymann G. Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection. J. Ocul. Pharmacol. Ther. 2008, 24:34-42.
17. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009 2009.
18. Kleymann G., Fischer R., Betz U.A., Hendrix M., Bender W., Schneider U., Handke G., Eckenber P., Hewlett G., Pevzner V., et al. New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease. Nat. Med. 2002, 8:392-398.
19. Kleymann G. Agents and strategies in development for improved management of herpes simplex virus infection and disease. Expert. Opin. Invest. Drugs 2005, 14:135-161.
20. Liuzzi M., Kibler P., Bousquet C., Harji F., Bolger G., Garneau M., Lapeyre N., McCollum R.S., Faucher A.-M., Simoneau B., Cordingley M.G. Isolation and characterization of herpes simplex virus type 1 resistant to aminothiazolylphenyl-based inhibitors of the viral helicase-primase. Antiviral Res. 2004, 64:161-170.
21. Nagafuchi S., Oda H., Mori R., Taniguchi T. Mechanism of acquired resistance to herpes simplex virus infection as studied in nude mice. J. Gen. Virol. 1979, 44:715-723.
22. Parris D.S., Harrington J.E. Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob. Agents Chemother. 1982, 22:71-77.
23. Spector F.C., Liang L., Giordano H., Sivaraja M., Peterson M.G. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 Complex. J. Virol. 1998, 72:6979-6987.
24. Sukla, S., Biswas, S., Birkmann, A., Lischka, P., Zimmermann, H., Field, H.J., 2010. Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor, J. Antimicrob. Chemother. (Epub ahead of print: May 7, 2010; ). doi:10.1093/jac/dkq135.
25. th Interscience Conference on Antimicrobial Agents and Chemotherapy 2009.
26. Weller S.K. HSV1 DNA Replication in Alphaherpesviruses: Molecular and Cellular Biology ed. Sandri-Goldwin RM 2006, Caister Academic Press.
27. Wilkins E.E., Howell P.I., Benedict M.Q. IMP PCR primers detect single nucleotide polymorphisms for Anopheles gambiae species identification, Mopti and Savanna rDNA types, and resistance to dieldrin in Anopheles arabiensis. Malaria J. 2006, 5:125-132.